Measuring & Improving Medical Affairs Impact

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from “Assessing the Impact of Medical Affairs: Measuring and Improving Impact”

STUDY OVERVIEW

Many Medical Affairs teams rely on outdated, execution-based metrics to convey their impact and value to the organization. This approach often falls short in linking activities to tangible business success and securing the necessary resources.

However, the landscape is shifting dramatically. Medical Affairs leaders are now under increasing pressure to demonstrate real-world outcomes, address care gaps, and enhance stakeholder engagements. The inability to measure these effectively can hinder your organization's growth and the recognition of your team’s contributions.

This Best Practices LLC benchmarking research delves into the metrics and strategies that Medical Affairs groups are adopting to measure and improve their impact. Spanning key topics such as measuring what matters, improving impact, and linking medical strategy to business success, this study offers detailed findings and industry benchmarks. Leverage the insights from this research to refine your measurement approaches, enhance your impact, and better connect your contributions to organizational goals.

KEY TOPICS

Measuring Impact
Enhancing Impact
Linking Medical Strategy to Business Success

KEY METRICS

Evolution of Medical Affairs impact measurement capabilities
Importance of key metrics for demonstrating Medical Affairs impact within the organization
Linking Medical impact to HCP behavior, patient outcomes, and ROI

SAMPLE KEY FINDINGS

Measuring Impact with Key Indicators: Improved outcomes (52%), reach (44%), influenced guidelines (29%), and activated clinicians / advocates (25%) are among the critical metrics which best indicate Medical impact within benchmark organizations.

METHODOLOGY

This Best Practices, LLC study engaged 34 Medical Affairs leaders who are improving Medical impact across 23 top biopharma organizations through a benchmarking survey. Deep-dive interviews were also conducted with participating Medical Affairs leaders to capture additional insights and nuances of impact.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Manufacturing; Health Care; Medical Device; Consumer Products; Clinical Research; Laboratories

Companies Profiled:
AbbVie; Alkermes; Astellas; AstraZeneca; Axsome Therapeutics; Biogen; BioMarin; Boehringer Ingelheim; Daiichi Sankyo; Eisai; Gilead Sciences; Jazz Pharmaceuticals; Johnson & Johnson; Novartis; Novo Nordisk; PDS Biotechnology; Pfizer; Regeneron; Sanofi; scPharmaceuticals; Takeda Pharmaceuticals; Vertex Pharmaceuticals; Viatris

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Assessing the Impact of Medical Affairs: Measuring and Improving Impact

ID: 5817

Features:

Pages/Slides: 27

Published: 2024

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
602F452E86AE7957E00258B7300276D66
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-assessing-impact-of-medical-affairs-measuring-improving-impact?opendocument
18
19opendocument
203.238.82.77
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB